Patents by Inventor Gabriel Kremmidiotis

Gabriel Kremmidiotis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATION AND USES THEREOF
    Publication number: 20210069147
    Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20200069729
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: November 9, 2019
    Publication date: March 5, 2020
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • Predictive biomarkers
    Patent number: 10564162
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 18, 2020
    Assignee: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Predictive baseline biomarkers for use of vascular disrupting agents
    Patent number: 10520508
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: December 31, 2019
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, Annabell Francis Leske
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 10213409
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: February 26, 2019
    Assignee: BIONOMICS LIMITED
    Inventors: Jason Hugh Chaplin, Gurmit Sing Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Combination treatment protocol
    Patent number: 10137105
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 27, 2018
    Assignee: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20180289739
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: February 20, 2018
    Publication date: October 11, 2018
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • PREDICTIVE BASELINE BIOMARKERS FOR USE OF VASCULAR DISRUPTING AGENTS
    Publication number: 20180196056
    Abstract: The present disclosure relates to the biological markers Ferritin and IL-8 that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE
  • PREDICTIVE BIOMARKERS
    Publication number: 20180196048
    Abstract: The present disclosure relates to the biological markers SAP, SHBG, Myoglobin, MMP-9, and SCF that are predictive for patient response to treatment with a vascular disrupting agent. In particular, the present disclosure relates to biological markers predictive for cancer patient response to treatment with a vascular disrupting agent, as well as methods of treating a cancer patient with a vascular disrupting agent.
    Type: Application
    Filed: July 2, 2015
    Publication date: July 12, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Annabell Francis LESKE
  • PHARMACEUTICAL COMBINATION AND USES THEREOF
    Publication number: 20180161302
    Abstract: The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
    Type: Application
    Filed: June 10, 2016
    Publication date: June 14, 2018
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
  • COMBINATION TREATMENT PROTOCOL
    Publication number: 20180042887
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Application
    Filed: March 2, 2016
    Publication date: February 15, 2018
    Applicant: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • A THERAPEUTIC PROTOCOL FOR TREATING OVARIAN CANCER
    Publication number: 20170119727
    Abstract: The present invention is directed to a pharmaceutical combination for treating proliferative disease comprising a compound of formula (I), or a salt, solvate or prodrug thereof, carboplatin or cisplatin, and gemcitabine. The present invention is further directed to a therapeutic protocol to manage ovarian cancer treatment in a female subject involving the administration of the combination to an ovarian cancer subject with recurrent or persistent ovarian cancer following treatment with platinum-based therapy. Kits comprising the combination as well as the use of the combination in the treatment of a proliferative disease are further contemplated.
    Type: Application
    Filed: May 30, 2014
    Publication date: May 4, 2017
    Applicant: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, David C. BIBBY, Danny RISCHIN
  • SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS
    Publication number: 20170020840
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.
    Type: Application
    Filed: April 28, 2016
    Publication date: January 26, 2017
    Inventors: JASON HUGH CHAPLIN, GURMIT SING GILL, DAMIAN WOJCIECH GROBELNY, BERNARD LUKE FLYNN, GABRIEL KREMMIDIOTIS
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 9346842
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: May 24, 2016
    Assignee: Bionomics Limited
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • COMBINATION THERAPY INVOLVING A VASCULAR DISRUPTING AGENT AND AN AGENT WHICH TARGETS HYPOXIA
    Publication number: 20150133401
    Abstract: The present invention provides a method for treating a proliferative disease in a patient. The method comprises administering to a patient in need thereof: a) a vascular disrupting agent and (b) at least one hypoxia targeting agent. Preferred combinations are BNC105 and Pazopanib and BNC 105 and Bortezomib.
    Type: Application
    Filed: June 3, 2013
    Publication date: May 14, 2015
    Inventors: Daniel J. Inglis, Tina C. Lavranos, Gabriel Kremmidiotis
  • Combination therapy for treating proliferative diseases
    Patent number: 9006284
    Abstract: A pharmaceutical composition of a tubulin polymerisation inhibitor and an mTOR inhibitor and a method of treating proliferative disease with a combination of a tubulin polymerisation inhibitor and an mTOR inhibitor.
    Type: Grant
    Filed: August 25, 2010
    Date of Patent: April 14, 2015
    Assignee: Bionomics Limited
    Inventors: Gabriel Kremmidiotis, David Bibby, Annabell Leske
  • Combination Therapy for Treating Proliferative Diseases
    Publication number: 20140248375
    Abstract: The present invention relates generally to new chemical combinations and methods for their use in the treatment of proliferative diseases and in particular cancer.
    Type: Application
    Filed: May 16, 2014
    Publication date: September 4, 2014
    Applicant: BIONOMICS LIMITED
    Inventors: Gabriel Kremmidiotis, Annabell Leske, Tina Lavranos
  • SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS
    Publication number: 20140171642
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors.
    Type: Application
    Filed: February 19, 2014
    Publication date: June 19, 2014
    Applicant: BIONOMICS LIMITED
    Inventors: JASON HUGH CHAPLIN, GURMIT SINGH GILL, DAMIAN WOJCIECH GROBELNY, BERNARD LUKE FLYNN, GABRIEL KREMMIDIOTIS
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 8716335
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: May 1, 2012
    Date of Patent: May 6, 2014
    Assignee: Bionomics Limited
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis
  • Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
    Patent number: 8680135
    Abstract: The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerization inhibitors.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: March 25, 2014
    Assignee: Bionomics Limited
    Inventors: Jason Hugh Chaplin, Gurmit Singh Gill, Damian Wojciech Grobelny, Bernard Luke Flynn, Gabriel Kremmidiotis